GlassScriptPhysician profile
Samuel A Johnson
NPI 1225255128
$3,385.00
in general payments reported to CMS, 2019-2025
26 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $143 · 2021: $209 · 2022: $1,063 · 2023: $316 · 2024: $448 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $968.89 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $374.97 | 2019-2025 | Farxiga |
| Akebia Therapeutics INC | $301.15 | 2019-2023 | Auryxia |
| Novartis Pharmaceuticals Corporation | $258.61 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $244.43 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $150.47 | 2022-2024 | Thiola |
| Fresenius USA Marketing, INC. | $147.32 | 2019-2024 | Velphoro |
| Bard Peripheral Vascular, INC. | $137.33 | 2019-2025 | Covera, Set Aspirex S 10f 110cm |
| Horizon Therapeutics Plc | $105.11 | 2019-2022 | |
| Baxter Healthcare | $80.60 | 2024 | Renal - Chronic |
| Mallinckrodt Enterprises LLC | $70.84 | 2019 | |
| Amgen INC. | $70.17 | 2022-2023 | Tavneos |
| Mallinckrodt Hospital Products INC. | $67.34 | 2025 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $59.20 | 2021-2025 | |
| Nxstage Medical, INC. | $54.02 | 2025 | Nxstage System One, Nxstage Cartridge Express, Liberty Select Cycler |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $38.52 | 2022-2025 | Purified Cortrophin Gel |
| Philips North America LLC | $34.50 | 2025 | IV Other, Labosys |
| Argon Medical Devices, INC. | $33.62 | 2023 | Cleaner |
| Vifor Pharma, INC. | $31.75 | 2019-2023 | Veltassa, Korsuva |
| Alexion Pharmaceuticals, INC. | $28.10 | 2024 | Ultomiris |
| Daiichi Sankyo INC. | $26.20 | 2019 | |
| Cycle Pharmaceuticals INC | $23.18 | 2025 | Ormalvi |
| Calliditas Therapeutics US INC. | $21.27 | 2024 | |
| Convatec INC. | $20.14 | 2024 | |
| Lundbeck LLC | $19.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.31 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.